find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
Advanced Solid Tumors
Phase I/II
Enrolling
nct/study# NCT04145622 / DS7300-A-J101
Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects With Advanced Solid Malignant Tumors
Learn More
Prostate Cancer Clinical Trials
Phase I/II
Enrolling
nct/study# NCT06267729 / D9660C00001-APOLLO
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against STEAP2, in Adult Participants with Metastatic Prostate Cancer
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06778863 / CLSP-1025-101
A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients with Solid Tumors that harbor the TP53-R175H Mutation
Learn More
Advanced Solid Tumors, NSCLC
Phase I
Enrolling
nct/study# NCT05117476 / CLN-619-001
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Learn More
Advanced Lung Cancer
Phase I
Enrolling
nct/study# NCT06892548 / BNT324-01
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer
Learn More
Esophageal, Gastric, Gastroesophageal Junction, Pancreatic
Phase I
Enrolling
nct/study# NCT05539430 / LB1908-1001
A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.